Postpartum hair loss and copper peptides: how to read claims carefully

TL;DR

• Postpartum shedding has a recognizable timeline, but one questionnaire’s high percentage came from a low-response survey that may have attracted more people with hair loss.¹
• GHK-Cu is a defined copper complex, yet knowing its chemical name does not establish a postpartum scalp outcome or connect a paper to a catalog item.²
• A topical delivery study reported hair-related findings in mice, while a separate AHK-Cu paper tested isolated follicles and cells rather than postpartum participants.³
• The Philippine FDA-hosted cosmetic guideline lists arresting hair loss and stimulating hair growth among unacceptable claims for hair-care cosmetics.⁴

For Filipino readers, a postpartum hair post may arrive between baby-care tips, testimonials, and ingredient explainers. The hard part is not learning one more scientific name. It is seeing where a familiar experience ends and a product claim begins. Pregnancy hair-cycle research, a mouse experiment, and an isolated follicle test can all be worth reading.³ They still answer different questions.³

Begin with the hair cycle

Hair follicles move through growing and resting phases called anagen and telogen.⁵ A comparative study used scalp imaging in 116 women sampled at several stages of pregnancy and after delivery.⁵ Mean anagen rates were lower in the fourth postpartum month than in the sixth and ninth months of pregnancy.⁵ Mean telogen rates were higher at that postpartum point.⁵

That pattern explains why a delayed wave of shedding can seem sudden even though the cycle shifted earlier.⁵ It does not identify the cause of every strand on a pillow or shower drain.⁶ The study also said that most participants did not show an exaggerated change.⁵ A sound explainer therefore describes the timing without turning it into a diagnosis for every new parent.⁵

GHK-Cu is named here only as the neutral catalog reference below.²

Timing estimates need their method

A later questionnaire study offers a more detailed timeline.¹ Researchers analyzed 331 responses completed 10 to 18 months after delivery.¹ Among those respondents, 91.8 percent recalled postpartum hair loss.¹ Their average reported start was 2.9 months, the peak was 5.1 months, and the end was 8.1 months.¹

These numbers are useful as descriptions of that respondent group.¹ They are not a clock that every Filipino parent must follow.¹ Only 21 percent of the invited group produced analyzed responses, and the authors noted possible recall and sampling bias.¹ Someone worried about shedding may have been more motivated to answer.¹

Good content keeps both halves together: the reported timeline and the way it was collected.¹ Dropping the second half makes a survey estimate sound like a universal biological schedule.¹

A large percentage is not a local prevalence figure

The literature does not provide one clean percentage that can be pasted onto a Philippines headline.⁷ A 2016 review called the entity poorly defined and said its exact incidence was unknown.⁸ The later questionnaire found a much higher self-reported percentage in its responding group.¹ Another study enrolled only women who already had postpartum hair loss.⁶

Those records use different doors into the research question.⁷ One reviews sparse objective work, one asks people to remember their experience, and one examines a symptomatic clinic group.⁷ Their percentages are not interchangeable population estimates.⁷

For a Filipino audience, the careful local framing is the reader context, not an invented national statistic.⁷ Say “after childbirth” or “for readers in the Philippines,” then keep each number attached to its country, sample, and method.⁷

One shedding story may contain several patterns

Postpartum timing does not guarantee that every visible change has one explanation.⁶ In an Egyptian study, clinicians examined 200 women who already reported postpartum hair loss.⁶ They used clinical assessment and dermoscopy, which is magnified inspection of the scalp and follicles.⁶

Only 9.5 percent were classified with telogen effluvium alone.⁶ The other participants were classified with additional androgenetic alopecia, traction alopecia, or both.⁶ These results do not describe all new parents because the group was selected for symptoms.⁶ They also do not supply a Philippine prevalence figure.⁶

The content lesson is narrower and more useful.⁶ A before-and-after photo cannot separate overlapping hair patterns by itself.⁶ Posts should avoid diagnosing a viewer from timing, hairstyle, or a single image.⁶ A study of a clinic group supports careful language, not a universal label.⁶

Copper-peptide names are not interchangeable

GHK is short for glycyl-L-histidyl-L-lysine, a three-amino-acid peptide.² When it binds copper(II), the complex is called GHK-Cu.² That name is more precise than the broad label copper peptide.² It still says nothing by itself about a postpartum hair result.²

A frequently cited hair experiment tested AHK-Cu, not GHK-Cu.⁹ AHK-Cu begins with alanine rather than glycine.⁹ Researchers reported elongation in isolated human hair follicles and proliferation in cultured dermal papilla cells.⁹ “Human follicle” sounds clinical, but the follicles were studied outside a person.⁹

Changing the first amino acid changes the named molecule.⁹ Moving from a dish to a postpartum participant changes the research question.⁹ Content overreaches when it erases either difference and presents the result as direct proof for GHK-Cu in new parents.³

Glutathione is named here only as the neutral catalog reference below.

A delivery experiment is not a postpartum outcome

A 2023 study designed an ionic-liquid microemulsion to move GHK-Cu through skin more effectively.¹⁰ The researchers reported about three-fold greater local delivery with their formulation.¹⁰ They then measured hair-related outcomes and pathway signals in mice.¹⁰

That record contains two linked questions: whether the carrier changed delivery and what happened in the animal model.¹⁰ Neither question enrolled postpartum participants.¹⁰ The result also belongs to the tested formulation, not every item that shares an ingredient name.¹⁰

Mechanism language needs the same restraint.¹⁰ The paper measured signals in the Wnt and beta-catenin pathway, which is involved in hair-growth regulation.¹⁰ A pathway change can help explain a mouse observation.¹⁰ It cannot supply a human outcome that the experiment did not measure.¹⁰

Human evidence can still answer another question

One randomized GHK-Cu study did involve people, but it was not a scalp-hair study.¹¹ Thirteen patients completed a comparison of skin-care routines after carbon-dioxide laser resurfacing around the mouth.¹¹ Researchers assessed redness, wrinkles, skin quality, and participant satisfaction over 12 weeks.¹¹

Objective assessment found no significant between-group improvement in redness, wrinkles, or overall skin quality.¹¹ Satisfaction was higher in the GHK-Cu group.¹¹ Both findings belong in a fair summary because the objective and reported outcomes differed.¹¹

The study cannot be repurposed as evidence for postpartum shedding.¹¹ “Human,” “randomized,” and “GHK-Cu” are not enough to make it relevant to every claim.¹¹ The body site, condition, comparator, outcome, and sample still have to match the sentence being written.³

Keep the claim inside the cosmetic boundary

The Philippine FDA hosts the ASEAN guideline used to assess cosmetic claims.⁴ It says a cosmetic should not be presented as treating or preventing disease in people.⁴ For hair-care products, its examples of unacceptable claims include arresting hair loss and stimulating hair growth.⁴

That boundary is useful for anyone drafting a caption, carousel, product page, or testimonial in the Philippines.⁴ A sentence about a mouse hair-related outcome stays close to the record.¹⁰ Turning it into a postpartum result changes the model, population, and certainty.³ It also creates wording outside the cosmetic guideline’s examples.⁴

Soft tone alone does not repair an unsupported claim.⁴ Adding “may,” “helps,” or a personal story cannot turn the wrong molecule or model into direct postpartum evidence.³ Accuracy comes from matching the noun, study, and outcome.³

Bottom line

Postpartum hair content becomes more useful when it separates experience from explanation.⁷ Hair-cycle studies describe a delayed pattern, but published frequency estimates depend heavily on sampling and method.⁵ A symptomatic clinic study also shows that more than one hair-loss pattern can appear in the same group.⁶

Copper-peptide research needs equally careful labels.³ GHK-Cu mouse delivery work, AHK-Cu follicle experiments, and a small GHK-Cu skin study are not one postpartum evidence package.³ For Filipino readers, the clearest rule is simple: name the molecule, model, body site, and measured outcome before repeating the finding.³ Stop before the study becomes a diagnosis, promise, or catalog claim.⁴

This article is educational research context, not medical advice. Catalog links are neutral references and do not imply a treatment or human-use recommendation.

Frequently asked questions

What is postpartum telogen effluvium?

The term describes delayed shedding linked to a shift from the growing anagen phase toward the resting telogen phase after delivery.⁵ In one comparative study, fourth-month postpartum measurements differed from later-pregnancy groups.⁵ That pattern does not diagnose every person who notices hair change after childbirth.⁶

When did shedding occur in the questionnaire study?

Among 331 analyzed respondents, the average recalled start was 2.9 months after delivery, the peak was 5.1 months, and the end was 8.1 months.¹ Those are group averages from a low-response, recall-based survey, not deadlines for an individual reader.¹

Does breastfeeding cause postpartum hair loss?

The questionnaire study found an association between longer breastfeeding and reported hair loss.¹² Its cross-sectional design cannot establish cause.¹² A separate hair-cycle study found different fourth-month anagen and telogen patterns between breastfeeding and non-breastfeeding groups, but no significant difference in the first postpartum year.⁵

Is AHK-Cu the same as GHK-Cu?

No. AHK-Cu starts with alanine, while GHK-Cu starts with glycine.² The cited AHK-Cu paper reported changes in isolated human follicles and cultured cells.⁹ Those findings should not be silently relabeled as direct GHK-Cu evidence or as a whole-person postpartum result.⁹

Did the GHK-Cu mouse study test new parents?

The study tested a topical delivery system and hair-related outcomes in mice.¹⁰ It reported greater local delivery for that formulation and measured pathway signals in the animal model.¹⁰ These findings do not describe postpartum participants and do not establish an outcome for a catalog item.¹⁰

Why does the Philippine cosmetic guideline matter here?

The Philippine FDA-hosted guideline ties cosmetic status partly to product presentation and claims.⁴ It lists arresting hair loss and stimulating hair growth as unacceptable claims for hair-care cosmetics.⁴ The list is illustrative rather than a final ruling on every product question.⁴

Sources

Footnotes

1. Investigation of exacerbating factors for postpartum hair loss: a questionnaire-based cross-sectional study. Cross-sectional questionnaire study at two facilities, based on 331 analyzed responses from a 21 percent response rate. The authors noted recall error and sampling bias because people with hair loss may have been more likely to participate. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³ ↩¹⁴

2. The human tri-peptide GHK and tissue remodeling. Narrative review of GHK and GHK-Cu identity and tissue-remodeling research. Chemical identity does not establish a hair outcome, postpartum relevance, or the identity and quality of a catalog item. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷

3. Thermodynamically stable ionic liquid microemulsions pioneer pathways for topical delivery and peptide application; The effect of tripeptide-copper complex on human hair growth in vitro; Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Comparison of three canonical study records with different experimental questions. Their findings cannot be combined into one postpartum hair-treatment result. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹

4. Appendix III – ASEAN Cosmetic Claims Guidelines. Official cosmetic-claims decision guidance hosted by the Philippine Food and Drug Administration. The guideline says its examples are not exhaustive and should not be treated as the final authority for every product classification question. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹

5. The changes in the hair cycle during gestation and the post-partum period. Trichoscan measurements in separate groups sampled during pregnancy, the fourth postpartum month, and the first postpartum year. The groups contained different participants, and the authors said the changes were not exaggerated in most women. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹

6. Postpartum Telogen Effluvium Unmasking Additional Latent Hair Loss Disorders. Selected clinical group in Egypt evaluated for coexisting hair-loss patterns. These percentages describe a symptomatic clinical sample and are not prevalence estimates for all postpartum people or for the Philippines. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³ ↩¹⁴ ↩¹⁵

7. The Postpartum Telogen Effluvium Fallacy; Investigation of exacerbating factors for postpartum hair loss: a questionnaire-based cross-sectional study; Postpartum Telogen Effluvium Unmasking Additional Latent Hair Loss Disorders. Comparison of a literature review, a low-response questionnaire survey, and a selected symptomatic clinical group. None of these records provides a Philippine population estimate. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷

8. The Postpartum Telogen Effluvium Fallacy. Retrospective review of two earlier studies that attempted objective measurement. This conclusion reflects the studies available to that 2016 review and should not be converted into a claim that postpartum shedding never occurs. ↩

9. The effect of tripeptide-copper complex on human hair growth in vitro. Ex vivo human hair-follicle organ culture and in vitro dermal papilla cell experiments. AHK-Cu has a different amino-acid sequence from GHK-Cu, and isolated follicles and cells do not establish a whole-person postpartum result. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸

10. Thermodynamically stable ionic liquid microemulsions pioneer pathways for topical delivery and peptide application. Formulation development, delivery experiments, pathway measurements, and hair-related experiments in mice. The mouse and delivery results do not establish a postpartum hair outcome in people or a result for a catalog item. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³ ↩¹⁴

11. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Small randomized comparison of skin-care regimens after circumoral carbon-dioxide laser resurfacing. This was a skin recovery study, not a study of scalp hair, postpartum shedding, or a catalog item. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸

12. Investigation of exacerbating factors for postpartum hair loss: a questionnaire-based cross-sectional study. Cross-sectional logistic regression using participant recall 10 to 18 months after delivery. An association from this design does not establish that breastfeeding or preterm labor caused the reported hair loss. ↩ ↩²